Resilience shells out $110M for bluebird bio site, kickstarting new collaboration

Just a little more than two years after bluebird bio purchased a manufacturing facility and spent another $80 million on upgrades, the company has spun around and sold it.

Resilience has acquired bluebird’s North Carolina lentiviral vector manufacturing facility for $110 million. The 125,000-square-foot site in Durham, NC, includes drug substance and drug product production suites, quality control labs and warehouse space. There’s also room for future expansion.